Green Rush Science (GRS), Inc. is an Oregon based company whose mission is to pioneer the emerging clinical cannabis pharmaceutical industry via neuro-cannabinoid drug solutions and advancements in cannabis medical science.
GRS is the parent company to its subsidiary and mainstay clinical research entity Nightingale Bioscience, LLC. Nightingale’s current research study aims to provide solid science-based evidence on the efficacy of Cannabis medicine in the Amyotrophic Lateral Sclerosis (ALS) disease. Our initial drug formulation is aimed primarily at slowing the progression of the disease as well as Delay of Onset in high risk patients while improving Quality of Life (QoL) symptoms relief. Nightingale Bioscience, LLC is an Oregon subsidiary of GRS and focuses on neuro-cannabinoid clinical research.
GRS is also positioned to stimulate the clinical cannabis markets through its charitable pillars. The GRS vehicle for this operation is its sister 501(c)(3) non-profit organization called The Green Rush Science & Love Foundation (GRSLove.org). The GRSLove pillars of excellence are: